Which has higher earnings and valuation, BIIB or KYMR?

Biogen has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $10.03B 3.22 $1.29B $5.65 38.67 Kymera Therapeutics $39.21M 250.55 -$311.35M -$3.24 N/A

Does the media refer more to BIIB or KYMR?

In the previous week, Biogen had 19 more articles in the media than Kymera Therapeutics. MarketBeat recorded 36 mentions for Biogen and 17 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.53 beat Biogen's score of 1.25 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 26 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 13 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor KYMR or ALNY?

In the previous week, Alnylam Pharmaceuticals had 10 more articles in the media than Kymera Therapeutics. MarketBeat recorded 27 mentions for Alnylam Pharmaceuticals and 17 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.53 beat Alnylam Pharmaceuticals' score of 1.14 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 13 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Alnylam Pharmaceuticals 21 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KYMR or BNTX?

In the previous week, BioNTech had 4 more articles in the media than Kymera Therapeutics. MarketBeat recorded 21 mentions for BioNTech and 17 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.53 beat BioNTech's score of 0.11 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 13 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BioNTech 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 5 Very Negative mention(s) Neutral

Is KYMR or INSM more profitable?

Insmed has a net margin of -76.94% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Kymera Therapeutics -285.33% -21.22% -19.21% Insmed -76.94% -123.94% -44.30%

Does the media favor KYMR or INSM?

In the previous week, Kymera Therapeutics had 10 more articles in the media than Insmed. MarketBeat recorded 17 mentions for Kymera Therapeutics and 7 mentions for Insmed. Kymera Therapeutics' average media sentiment score of 1.53 beat Insmed's score of 0.90 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 13 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Insmed 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, KYMR or INCY?

Incyte has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kymera Therapeutics $39.21M 250.55 -$311.35M -$3.24 N/A Incyte $5.14B 4.90 $1.29B $7.85 15.84

Is KYMR or INCY more profitable?

Incyte has a net margin of 27.71% compared to Kymera Therapeutics' net margin of -285.33%. Incyte's return on equity of 29.93% beat Kymera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kymera Therapeutics -285.33% -21.22% -19.21% Incyte 27.71% 29.93% 22.88%

Does the media prefer KYMR or INCY?

In the previous week, Incyte had 26 more articles in the media than Kymera Therapeutics. MarketBeat recorded 43 mentions for Incyte and 17 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.53 beat Incyte's score of 1.38 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 13 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Incyte 33 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Kymera Therapeutics (KYMR) Competitors

$118.15 -2.08 (-1.73%)

As of 08/28/2026 04:00 PM Eastern

Compare

KYMR vs. BIIB, ALNY, BNTX, INSM, and INCY

Should you buy Kymera Therapeutics stock or one of its competitors? Kymera Therapeutics's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioNTech (BNTX), Insmed (INSM), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kymera Therapeutics compare to Biogen?

Biogen (NASDAQ:BIIB) and Kymera Therapeutics (NASDAQ:KYMR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

87.9% of Biogen shares are held by institutional investors. 0.3% of Biogen shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Biogen presently has a consensus target price of $227.79, indicating a potential upside of 4.25%. Kymera Therapeutics has a consensus target price of $127.17, indicating a potential upside of 7.64%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kymera Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Biogen had 19 more articles in the media than Kymera Therapeutics. MarketBeat recorded 36 mentions for Biogen and 17 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.53 beat Biogen's score of 1.25 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	26 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	13 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Biogen has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market.

Biogen has a net margin of 8.32% compared to Kymera Therapeutics' net margin of -285.33%. Biogen's return on equity of 11.18% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Kymera Therapeutics	-285.33%	-21.22%	-19.21%

Biogen has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$10.03B	3.22	$1.29B	$5.65	38.67
Kymera Therapeutics	$39.21M	250.55	-$311.35M	-$3.24	N/A

Summary

Biogen beats Kymera Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Kymera Therapeutics compare to Alnylam Pharmaceuticals?

Kymera Therapeutics (NASDAQ:KYMR) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Kymera Therapeutics presently has a consensus price target of $127.17, indicating a potential upside of 7.64%. Alnylam Pharmaceuticals has a consensus price target of $386.14, indicating a potential upside of 62.86%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.88
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92

Kymera Therapeutics has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

In the previous week, Alnylam Pharmaceuticals had 10 more articles in the media than Kymera Therapeutics. MarketBeat recorded 27 mentions for Alnylam Pharmaceuticals and 17 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.53 beat Alnylam Pharmaceuticals' score of 1.14 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	13 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Alnylam Pharmaceuticals	21 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	250.55	-$311.35M	-$3.24	N/A
Alnylam Pharmaceuticals	$4.80B	6.60	$313.75M	$5.38	44.07

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Kymera Therapeutics' net margin of -285.33%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Summary

Alnylam Pharmaceuticals beats Kymera Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Kymera Therapeutics compare to BioNTech?

Kymera Therapeutics (NASDAQ:KYMR) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Kymera Therapeutics has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

BioNTech has a net margin of -63.54% compared to Kymera Therapeutics' net margin of -285.33%. BioNTech's return on equity of -6.86% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
BioNTech	-63.54%	-6.86%	-6.00%

Kymera Therapeutics currently has a consensus target price of $127.17, indicating a potential upside of 7.64%. BioNTech has a consensus target price of $127.81, indicating a potential upside of 25.22%. Given BioNTech's higher probable upside, analysts clearly believe BioNTech is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.88
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Kymera Therapeutics has higher earnings, but lower revenue than BioNTech. Kymera Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	250.55	-$311.35M	-$3.24	N/A
BioNTech	$3.25B	7.95	-$1.29B	-$7.83	N/A

15.5% of BioNTech shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, BioNTech had 4 more articles in the media than Kymera Therapeutics. MarketBeat recorded 21 mentions for BioNTech and 17 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.53 beat BioNTech's score of 0.11 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	13 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
BioNTech	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	5 Very Negative mention(s)	Neutral

Summary

BioNTech beats Kymera Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Kymera Therapeutics compare to Insmed?

Kymera Therapeutics (NASDAQ:KYMR) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Insmed has a net margin of -76.94% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
Insmed	-76.94%	-123.94%	-44.30%

Kymera Therapeutics has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market. Comparatively, Insmed has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

Kymera Therapeutics currently has a consensus target price of $127.17, indicating a potential upside of 7.64%. Insmed has a consensus target price of $205.52, indicating a potential upside of 73.38%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.88
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Kymera Therapeutics had 10 more articles in the media than Insmed. MarketBeat recorded 17 mentions for Kymera Therapeutics and 7 mentions for Insmed. Kymera Therapeutics' average media sentiment score of 1.53 beat Insmed's score of 0.90 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	13 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Insmed	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kymera Therapeutics has higher earnings, but lower revenue than Insmed. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	250.55	-$311.35M	-$3.24	N/A
Insmed	$606.42M	42.69	-$1.28B	-$4.11	N/A

Summary

Kymera Therapeutics beats Insmed on 8 of the 15 factors compared between the two stocks.

How does Kymera Therapeutics compare to Incyte?

Kymera Therapeutics (NASDAQ:KYMR) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, Incyte had 26 more articles in the media than Kymera Therapeutics. MarketBeat recorded 43 mentions for Incyte and 17 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.53 beat Incyte's score of 1.38 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	13 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Incyte	33 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

97.0% of Incyte shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Incyte has a net margin of 27.71% compared to Kymera Therapeutics' net margin of -285.33%. Incyte's return on equity of 29.93% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
Incyte	27.71%	29.93%	22.88%

Kymera Therapeutics has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market. Comparatively, Incyte has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

Kymera Therapeutics presently has a consensus price target of $127.17, suggesting a potential upside of 7.64%. Incyte has a consensus price target of $123.10, suggesting a potential downside of 1.02%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.88
Incyte	0 Sell rating(s)	12 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.56

Incyte has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	250.55	-$311.35M	-$3.24	N/A
Incyte	$5.14B	4.90	$1.29B	$7.85	15.84

Summary

Incyte beats Kymera Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Kymera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYMR vs. The Competition

Export

Metric	Kymera Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.00B	$4.02B	$7.24B	$12.93B
Dividend Yield	N/A	3.60%	2.54%	10.96%
P/E Ratio	-36.47	11.56	271.50	25.38
Price / Sales	250.55	1,345.97	624.00	96.54
Price / Cash	N/A	110.59	79.29	54.21
Price / Book	6.51	16.50	12.95	6.14
Net Income	-$311.35M	-$22.76M	$3.46B	$347.93M
7 Day Performance	-1.38%	-0.23%	-0.11%	-0.78%
1 Month Performance	12.26%	11.93%	8.32%	5.60%
1 Year Performance	186.77%	55.61%	24.64%	15.64%

Kymera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYMR Kymera Therapeutics	1.6511 of 5 stars	$118.15 -1.7%	$127.17 +7.6%	+183.0%	$10.00B	$39.21M	N/A	170	Positive News Analyst Forecast
BIIB Biogen	3.6022 of 5 stars	$222.19 +1.9%	$227.07 +2.2%	+64.7%	$32.86B	$9.89B	39.36	7,500	Positive News Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.8791 of 5 stars	$238.37 +1.0%	$386.62 +62.2%	-47.6%	$31.91B	$3.71B	44.32	2,770	News Coverage Positive News Analyst Forecast Gap Down
BNTX BioNTech	3.5039 of 5 stars	$116.51 +3.3%	$127.81 +9.7%	+0.1%	$29.46B	$3.25B	N/A	7,807	Trending News Options Volume Gap Down
INSM Insmed	3.3862 of 5 stars	$125.86 +1.5%	$205.52 +63.3%	-12.2%	$27.50B	$1.14B	N/A	1,664

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYMR) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kymera Therapeutics (KYMR) Competitors

KYMR vs. BIIB, ALNY, BNTX, INSM, and INCY

How does Kymera Therapeutics compare to Biogen?

Summary

How does Kymera Therapeutics compare to Alnylam Pharmaceuticals?

Summary

How does Kymera Therapeutics compare to BioNTech?

Summary

How does Kymera Therapeutics compare to Insmed?

Summary

How does Kymera Therapeutics compare to Incyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYMR vs. The Competition

Kymera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kymera Therapeutics (KYMR) Competitors

KYMR vs. BIIB, ALNY, BNTX, INSM, and INCY

How does Kymera Therapeutics compare to Biogen?

Do insiders and institutionals hold more shares of BIIB or KYMR?

Do analysts prefer BIIB or KYMR?

Does the media refer more to BIIB or KYMR?

Which has more volatility & risk, BIIB or KYMR?

Is BIIB or KYMR more profitable?

Which has higher earnings and valuation, BIIB or KYMR?

Summary

How does Kymera Therapeutics compare to Alnylam Pharmaceuticals?

Do analysts prefer KYMR or ALNY?

Which has more risk & volatility, KYMR or ALNY?

Does the media favor KYMR or ALNY?

Which has higher valuation & earnings, KYMR or ALNY?

Do institutionals and insiders believe in KYMR or ALNY?

Is KYMR or ALNY more profitable?

Summary

How does Kymera Therapeutics compare to BioNTech?

Which has more volatility & risk, KYMR or BNTX?

Is KYMR or BNTX more profitable?

Do analysts prefer KYMR or BNTX?

Which has preferable earnings and valuation, KYMR or BNTX?

Do insiders and institutionals believe in KYMR or BNTX?

Does the media refer more to KYMR or BNTX?

Summary

How does Kymera Therapeutics compare to Insmed?

Is KYMR or INSM more profitable?

Which has more risk & volatility, KYMR or INSM?

Do analysts prefer KYMR or INSM?

Does the media favor KYMR or INSM?

Which has preferable valuation and earnings, KYMR or INSM?

Summary

How does Kymera Therapeutics compare to Incyte?

Does the media prefer KYMR or INCY?

Do institutionals & insiders hold more shares of KYMR or INCY?

Is KYMR or INCY more profitable?

Which has more volatility and risk, KYMR or INCY?

Do analysts prefer KYMR or INCY?

Which has better valuation and earnings, KYMR or INCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYMR vs. The Competition

Kymera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools